Monopar

Wilmette, United States

Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.

$135.0M raised

Sep 2025

Post-IPO Equity

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Monopar raised?

Monopar has raised $135.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2025.

Who are Monopar's investors?

Monopar's investors include RA Capital Management, Janus Henderson Investors, Adage Capital Management, ADAR1 Capital Management.

Where is Monopar headquartered?

Monopar is headquartered in Wilmette, United States.

What does Monopar do?

Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.

What stage is Monopar at?

Monopar is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 23, 2025.

MLA

"Monopar — Funding & Investors." VCBacked, September 23, 2025, https://www.vcbacked.co/company/monopar. Accessed July 2, 2026.

APA

VCBacked. (2025). Monopar — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/monopar

Wikipedia (cite web)

{{cite web |title=Monopar — Funding & Investors |url=https://www.vcbacked.co/company/monopar |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 23, 2025.